LYON, France–(BUSINESS WIRE)–Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative formulations of proteins and...

Dec 21, 2022 (Nanowerk News) Researchers at the University of Tokyo have used artificial DNA to target and kill cancer cells in a completely...

In 2022, the clinical trials industry adjusted to post-pandemic reality, embracing new innovations that emerged from COVID-19. We expect many of these to continue:...

Preventing Strokes and Heart Attacks Doesn’t Have to Come with the Risk of Life-threatening Bleeding Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular...